Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, in Stockholm, Sweden, Thomas Alexander, MD, PhD, of the University of North Carolina School of Medicine, Chapel Hill, NC, discusses biomarker screening in the context of acute lymphoblastic leukemia (ALL). He speaks about a recent trial combining venetoclax, navitoxlax and chemotherapy in relapsed ALL (NCT03181126), and highlights the genomic and BH3 profiling that has been conducted in this cohort. He emphasizes the importance of moving beyond genomic profiling in the context of ALL treatment, suggesting that more rigorous functional assays are needed in order to properly understand disease biology on an individual level, allowing for more specialized care.
Using biomarkers and genomics to inform treatment strategy in ALL
